Net sales rose 58% year-over-year for H1 2025, with Q2 sales at record levels and gross margin reaching 70%. Operating losses narrowed significantly, driven by strong neurosurgery segment growth and cost reductions. Long-term outlook remains robust.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.